Euglow Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
- Paid Up Capital ₹ 3.36 M
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 3.50 M
- Revenue Growth 21.73%
- Profit Growth -33.18%
- Ebitda -71.15%
- Net Worth 0.73%
- Total Assets 1.92%
About Euglow Pharma
Euglow Pharma Limited (EPL) is a Public Limited Indian Non-Government Company incorporated in India on 28 December 2005 and has a history of 19 years and one month. Its registered office is in Thanjavur, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 3.36 M.
The company currently has active open charges totaling ₹3.50 M.
Narayanasamy Srinivasan, Krishnamoorthy Mohan, and Ramachandran Rajalakshmi serve as directors at the Company.
Company Details
-
Location
Thanjavur, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232TN2005PLC058444
-
Company No.
058444
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
28 Dec 2005
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Euglow Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narayanasamy Srinivasan
|
Managing Director | 28-Dec-2005 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Krishnamoorthy Mohan
|
Director | 03-Nov-2008 | Current |
|
Ramachandran Rajalakshmi
|
Director | 03-Nov-2008 | Current |
Financial Performance of Euglow Pharma.
Euglow Pharma Limited, for the financial year ended 2016, experienced significant growth in revenue, with a 21.73% increase. The company also saw a substantial fall in profitability, with a 33.18% decrease in profit. The company's net worth moved up by a moderate rise of 0.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Euglow Pharma?
In 2016, Euglow Pharma had a promoter holding of 65.48% and a public holding of 34.52%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Aarsree Apartments Private LimitedKrishnamoorthy Mohan is a mutual person
Charges (Loans)
₹3.50 M
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 0.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Feb 2012 | Indian Bank | ₹3.50 M | Open |
How Many Employees Work at Euglow Pharma?
Unlock and access historical data on people associated with Euglow Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Euglow Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Euglow Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
